GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virpax Pharmaceuticals Inc (NAS:VRPX) » Definitions » FCF Yield %

Virpax Pharmaceuticals (Virpax Pharmaceuticals) FCF Yield % : -1,019.24 (As of May. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Virpax Pharmaceuticals FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Virpax Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-15.57 Mil, and Market Cap is $1.53 Mil. Therefore, Virpax Pharmaceuticals's FCF Yield % for today is -1,019.24%.

The historical rank and industry rank for Virpax Pharmaceuticals's FCF Yield % or its related term are showing as below:

VRPX' s FCF Yield % Range Over the Past 10 Years
Min: -1802.55   Med: 0   Max: 0
Current: -1019.24


VRPX's FCF Yield % is ranked worse than
98.13% of 1554 companies
in the Biotechnology industry
Industry Median: -14.415 vs VRPX: -1019.24

Virpax Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


Virpax Pharmaceuticals FCF Yield % Historical Data

The historical data trend for Virpax Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virpax Pharmaceuticals FCF Yield % Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial - - -36.19 -244.82 -262.84

Virpax Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.34 -69.02 -113.17 -321.25 -619.45

Competitive Comparison of Virpax Pharmaceuticals's FCF Yield %

For the Biotechnology subindustry, Virpax Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virpax Pharmaceuticals's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virpax Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Virpax Pharmaceuticals's FCF Yield % falls into.



Virpax Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Virpax Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-9.854 / 3.74910723
=-262.84%

Virpax Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-7.729 * 4 / 4.990845276
=-619.45%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Virpax Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Virpax Pharmaceuticals FCF Yield % Related Terms

Thank you for viewing the detailed overview of Virpax Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Virpax Pharmaceuticals (Virpax Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
Executives
Sheila Mathias officer: Chief Scientific Officer 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Barbara Ruskin director C/O VIRPAX PHARMACEUTICALS, INC., 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jerrold Sendrow director C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Eric Floyd director C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Anthony P. Mack director, 10 percent owner, officer: Chief Executive Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Michael F Dubin director C/O VIRPAX PHARMACEUTICALS, 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Vanila Singh director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Gary S Jacob director
Christopher Michael Chipman officer: Chief Financial Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Jeffrey Gudin director, officer: Chief Medical Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Thani Jambulingam director C/O VIRAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Gerald W Bruce officer: EVP, Commercial Operations NITROMED INC, 125 SPRING STREET, LEXINGTON MA 02421
Virpax Pharmaceuticals Llc 10 percent owner C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380